- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07950475
Methodological Validation of Antera 3D for Quantitative Assessment of Atrophic Scars
This clinical study aims to establish standardised image acquisition and analysis methods using Antera 3D for the quantitative assessment of atrophic scars.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: HyeJung Park
- Phone Number: +82-70-44699115
- Email: hjpark@cillincills.com
Study Locations
-
-
-
Seoul, South Korea
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Individuals with Atroptic Scars
Description
Inclusion Criteria:
- Male or female participants aged 19 years or older
- Participants wit atrophic acars or in the temporal regions of tha face
- Participants with atrophic scars on the cheeks or in the temporal regions of the face for whom a circular region of interest (ROI) with a diameter of 2 cm can be defined for analysis (i.e., the ROI contains atrophic scars).
- Participants who voluntarily provide written informed consent to participate in the study.
Exclusion Criteria:
- Participants with infectious skin diseases or other forms of dermatitis affecting the face.
- Participants with serious acute, chronic, or progressive diseases that may preclude participation in the study.
- Participants who are considered unsuitable for participation in the study, as determined by the Investigator.
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
A Single Group
Participant with Atrophic Scar |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Test-retest repeatability of Depression Volume Measured Using Antera 3D
Time Frame: At Visit 1 (Day 1)
|
Test-retest repeatability of depression volume will be evaluated using the intraclass correlation coefficient (ICC) based on three independent image acquisitions of the same target region of interest (ROI) in each participant, with repositioning between acquisitions. Depression volume will be determined using Antera 3D image analysis software. |
At Visit 1 (Day 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Test-Retest Repeatability of Depression Area Measured Using Antera 3D
Time Frame: At Visit 1 (Day 1)
|
Test-retest repeatability of depression area will be evaluated using the intraclass correlation coefficient (ICC) based on three independent image acquisitions of the same target region of interest (ROI) in each participant, with repositioning between acquisitions. Depression area will be determined using Antera 3D image analysis software. |
At Visit 1 (Day 1)
|
|
Test-Retest Repeatability of Maximum Depth Measured Using Antera 3D
Time Frame: At Visit 1 (Day 1)
|
Test-retest repeatability of maximum depth will be evaluated using the intraclass correlation coefficient (ICC) based on three independent image acquisitions of the same target region of interest (ROI) in each participant, with repositioning between acquisitions. Maximum depth will be determined using Antera 3D image analysis software. |
At Visit 1 (Day 1)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CIC101-02-AN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.